Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells

Cutillas Aullo, Natalia; Ruiz López, José; Novohradsky, Vojtech; Marco Calero, Alicia; Markova, Lenka; Brabec, Viktor

Publication:
Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells

dc.contributor.author	Cutillas Aullo, Natalia
dc.contributor.author	Ruiz López, José
dc.contributor.author	Novohradsky, Vojtech
dc.contributor.author	Marco Calero, Alicia
dc.contributor.author	Markova, Lenka
dc.contributor.author	Brabec, Viktor
dc.contributor.department	Química Inorgánica
dc.date.accessioned	2024-04-11T22:11:14Z
dc.date.available	2024-04-11T22:11:14Z
dc.date.copyright	© 2023 The Authors
dc.date.issued	2023-06-06
dc.description.abstract	Herein, we report a series of new octahedral iridium(III) complexes Ir1–Ir9 of the type [Ir(N^N^N)(C^N)Cl]PF6 (N^N^N = 4′-(p-tolyl)-2,2′:6′,2″-terpyridine; C^N = deprotonated 2-arylbenzimidazole backbone) to introduce new metal-based compounds for effective inhibition of metastatic processes in triple-negative breast cancer (TNBC). The results show that the structural modifications within the C^N scaffold strongly impact the antimetastatic properties of these complexes in TNBC cells. Furthermore, testing the antimetastatic effects of the investigated Ir complexes revealed that the highest antimetastatic activity in TNBC cells is exhibited by complex Ir1. This result was in contrast to the effects of the clinically used drug doxorubicin used in conventional chemotherapy of TNBC, which conversely promoted metastatic properties of TNBC cells. Thus, the latter result suggests that doxorubicin chemotherapy may increase the risk of metastasis of breast cancer cells, so the search for new drugs to treat breast cancer that would show better antitumor effects than doxorubicin is justified.
dc.format	application/pdf	es_ES
dc.format.extent	18
dc.identifier.citation	Journal of Medicinal Chemistry 2023, 66, 9766−9783
dc.identifier.doi	https://doi.org/10.1021/acs.jmedchem.3c00586
dc.identifier.issn	Print: 0022-2623
dc.identifier.issn	Electronic: 1520-4804
dc.identifier.uri	http://hdl.handle.net/10201/140744
dc.language	eng	es_ES
dc.publisher	American Chemical Society
dc.relation.publisherversion	https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00586?ref=PDF
dc.rights	info:eu-repo/semantics/openAccess	*
dc.rights	Atribución 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	Antineoplastic agents	es_ES
dc.subject	Cancer	es_ES
dc.subject	Cells	es_ES
dc.subject	Genetics	es_ES
dc.subject	Transition metals
dc.title	Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells	es_ES
dc.type	info:eu-repo/semantics/article	es_ES
dc.type.version	info:eu-repo/semantics/publishedVersion
dspace.entity.type	Publication	es